Background -The activity of the reninangiotensin system in asthma has not been studied previously and the effect of angiotensin II (AII) on bronchomotor tone in vivo is unknown. Methods -Plasma levels of renin and AII levels were measured in 20 patients with acute severe asthma, nine with mild asthma, 10 with severe chronic asthma, and 16 normal volunteers. The effect of AII, given as an intravenous infusion, on bronchomotor tone was also investigated in eight mild asthmatic patients. Results -In acute severe asthma plasma levels of renin [median (interquartile range)] were elevated on days 1, 2, and 5 after admission [48-7 (24-79), 44-2 (15-75), and 45 5 (21-70) ,uU/ml, respectively].
The renin-angiotensin system plays an important part in the regulation of cardiovascular homoeostasis and electrolyte balance. ' The effector hormone of the system is the octapeptide angiotensin II (AII) which is a potent vasoconstrictor of vascular smooth muscle and a stimulus for the secretion of aldosterone from the adrenal gland.2 In addition, recent in vitro work has shown that AII can potentiate bronchoconstriction of rabbit airway smooth muscle,3 although the direct effects of AII on bronchomotor tone and reactivity in man have not previously been described.
In a preliminary study we found evidence of considerable activation of the renin-angiotensin system in acute severe asthma. We therefore measured plasma levels of renin and AII in a group of patients with acute severe asthma and compared the results with those obtained in patients with stable chronic asthma and a non-asthmatic control group. Since AII may have several potentially adverse effects on pulmonary function, including bronchoconstriction, we were also interested in examining the effect of AII on lung function in vivo in mild asthmatic patients.
Methods STUDY 1: ACTIVITY OF THE RENIN-ANGIOTENSIN SYSTEM IN ACUTE SEVERE ASTHMA
Plasma levels of renin and AII were measured in four groups of subjects. Group 1 comprised 20 patients (six men) of mean (SD) age 34 (12 9) years admitted non-consecutively (two patients admitted twice) to Accident and Emergency with acute severe asthma (PEF 125 (38) 1/min, Pao2 9 2 (3 3) kPa (on air), pulse rate 120 (15) beats/min on admission). Venous blood was withdrawn shortly after admission for estimation of plasma renin and AII levels and measurements were repeated on days 2 and 5 after admission. All had received nebulised 02 agonists (salbutamol) and four were given intravenous hydrocortisone in Accident and Emergency prior to venesection. Seventeen patients were taking regular inhaled corticosteroids, five oral theophylline, and 10 were on oral prednisolone. (fig 1) . There was no significant difference in plasma levels of renin and AlI when severe chronic asthma, mild chronic asthma, and control groups were compared. Blood pressure and heart rate Blood pressure did not change significantly during infusion of placebo. Following infusion of AII, however, there were significant rises (p < 0 05) in both systolic (fig 2) and diastolic levels. There were no significant changes in heart rate during infusion of placebo or AII (data not shown). agonist therapy used in the treatment of acute asthma may be responsible for this activation. In support of this suggestion was our observation that plasma levels of renin and AII remained elevated on days 2 and 5 when the patients were recovering from the acute attack of asthma (as demonstrated by increased peak flow rates) but still receiving nebulised bronchodilator therapy. In addition, Phillips et alP observed an increase in plasma renin activity following intravenous infusion of salbutamol in four healthy male subjects, and Scheinin et al7 found a dose dependent increase in plasma levels of renin after both fenoterol and salbutamol administered by metered dose inhaler to six normal subjects.
Hypoxia may also cause activation of the renin-angiotensin system, although studies which have examined this effect in animals and in man have produced conflicting results. Rats exposed to chronic hypoxia develop a rise in renin and renin substrate,8 although hypoxia has been reported to reduce the ability of the lung to convert angiotensin I to angiotensin II in anaesthetised dogs.9 In stable cor pulmonale the renin-angiotensin system has been reported not to be activated,'0 while others have observed elevated levels of AII in patients with airflow obstruction and arterial hypoxaemia."1
Other stimuli which could cause activation of the renin-angiotensin system in acute severe asthma include circulating catecholamines. Ind et al have reported elevated noradrenaline levels in acute asthma, although adrenaline levels appear to rise only in the most severe cases.'2 We have not found evidence of this in our study where plasma catecholamines were in the normal range (data not shown). Other stimuli are hypovolaemia and drugs such as diuretics. However, none of our patients with acute asthma was clinically dehydrated and only one was taking regular oral diuretic therapy. The role of other inflammatory mediators on the activity of the renin-angiotensin system -for example, histamine or prostaglandins -is unclear, although it is of interest that proteinases secreted by mast cells have been shown rapidly to convert angiotensin I to angiotensin II by an angiotensin converting enzyme independent pathway. '3 AII has recently been shown to potentiate vagal mediated contraction of rabbit airway smooth muscle through the activation of prejunctional receptors,3 thus raising the possibility that it may have bronchoconstrictor activity in the human airway. In our second study we showed that AII causes bronchoconstriction when administered intravenously to mild asthmatic patients. The exact mechanism of bronchoconstriction by AII is uncertain, but could be either a direct effect on airway smooth muscle or perhaps even the result of release of other mediators of bronchoconstriction such as endothelin. '4 Another possible mechanism is a reflex increase in vagal tone secondary to the rise in blood pressure, although it is interesting to note that heart rate did not increase in our study. As the range of plasma levels of AII achieved during the infusions is comparable to that found in our acute asthma study, we could therefore hypothesise that this hormone may contribute to a proportion of the bronchoconstriction in acute severe asthma.
It is interesting to consider further how AII could have potential adverse effects on the asthmatic airway. AII is also known to cause pulmonary vasoconstriction and hypoxaemial5 which could contribute to ventilation-perfusion imbalance during acute asthma or cause reduced clearance of inflammatory mediators. Other reported actions of AII include increased vascular permeability in experimental animals, raising the possibility that elevated levels of this hormone in asthma could contribute to the inflammatory response within the airway. AII has also been reported to promote the growth of cultured vascular smooth muscle cells in vitro. '6 If such effects occurred on airway smooth muscle as a result of generation of excess angiotensin II in the lungs, this may be of importance in the long term by contributing to the development of airway smooth muscle hypertrophy.
In conclusion, we have observed activation of the renin-angiotensin system in patients with acute severe asthma and have also shown that this hormone causes bronchoconstriction in vivo in man. These observations pose the hypothesis that AII may contribute to bronchoconstriction during acute severe asthma.
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